» Articles » PMID: 23163236

Autism and Other Psychiatric Comorbidity in Neurofibromatosis Type 1: Evidence from a Population-based Study

Overview
Date 2012 Nov 21
PMID 23163236
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate psychopathology in children with neurofibromatosis type 1 (NF1), particularly the prevalence of autism spectrum disorder (ASD) and attention-deficit-hyperactivity disorder (ADHD) symptomatology, using a population-based sampling approach.

Method: Standard questionnaire screen reports were analysed for ASD (Social Responsiveness Scale, SRS), ADHD (Conners' Parent Rating Scale- Revised, CPRS-R), and other psychiatric morbidity (Strengths and Difficulties Questionnaire, SDQ) from parents and teachers of children aged from 4 to 16 years (112 females, 95 males) on the UK North West Regional Genetic Service register for NF1.

Results: Parental response rate was 52.7% (109/207 children; 59 females, 50 males, mean age 9 y 11 mo, SD 3 y 3 mo). The SRS showed that in 29.4% (32/109) of children, autism was in the severe, clinical range (T-score>75) and in 26.6% (29/109) in the mild to moderate range (T-score 60-75). CPRS-R scores showed that in 53.8% (57/106) of children autism was in the clinical ADHD range (ADHD index T-score>65). Based on their scores on the SDQ total difficulties scale, 41.5% (44/106) of children were in the abnormal range and 14.2% (15/106) were in the borderline range. Twenty-five per cent (26/104) of children met criteria for both clinical autism and ADHD.

Interpretation: This representative population-based sample of children with NF1 indicates a high prevalence of ASD symptoms associated with NF1 as well as substantial co-occurrence with ADHD symptoms. The findings clarify the psychopathology of NF1 and show the disorder as a potentially important single-gene cause for autism symptoms.

Citing Articles

Disrupted visual attention relates to cognitive development in infants with Neurofibromatosis Type 1.

Begum-Ali J, Mason L, Charman T, Johnson M, Green J, Garg S J Neurodev Disord. 2025; 17(1):12.

PMID: 40087579 DOI: 10.1186/s11689-025-09599-4.


Developmental trajectories in infants and pre-school children with Neurofibromatosis 1.

Slevin H, Kehinde F, Begum-Ali J, Ellis C, Burkitt-Wright E, Green J Mol Autism. 2024; 15(1):45.

PMID: 39407332 PMC: 11481376. DOI: 10.1186/s13229-024-00621-5.


Social Communication in Ras Pathway Disorders: A Comprehensive Review From Genetics to Behavior in Neurofibromatosis Type 1 and Noonan Syndrome.

Siqueiros-Sanchez M, Serur Y, McGhee C, Smith T, Green T Biol Psychiatry. 2024; 97(5):461-498.

PMID: 39366539 PMC: 11805629. DOI: 10.1016/j.biopsych.2024.09.019.


Impact of pathogenic variants of the Ras-mitogen-activated protein kinase pathway on major white matter tracts in the human brain.

Siqueiros-Sanchez M, Dai E, McGhee C, McNab J, Raman M, Green T Brain Commun. 2024; 6(4):fcae274.

PMID: 39210910 PMC: 11358645. DOI: 10.1093/braincomms/fcae274.


A Comparison of Effectiveness of Attention Process Training (APT) with Parenting Management Training (PMT) in Reducing Symptoms of Attention Deficit Hyperactivity Disorder.

Nadermohammadi Moghadam M, Bakhshi P, Azarkollah A, Moulai B, Molavi P Iran J Psychiatry. 2024; 19(3):254-264.

PMID: 39055521 PMC: 11267122. DOI: 10.18502/ijps.v19i3.15802.